United States of America Department of Justice v. Daniel Chapter One

89 F. Supp. 3d 132, 2015 U.S. Dist. LEXIS 42751
CourtDistrict Court, District of Columbia
DecidedMarch 31, 2015
DocketCivil Action No. 2010-1362
StatusPublished
Cited by5 cases

This text of 89 F. Supp. 3d 132 (United States of America Department of Justice v. Daniel Chapter One) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America Department of Justice v. Daniel Chapter One, 89 F. Supp. 3d 132, 2015 U.S. Dist. LEXIS 42751 (D.D.C. 2015).

Opinion

MEMORANDUM OPINION

Emmet G. Sullivan, United States District Judge

This case involved certain dietary supplements that defendants claimed could treat, cure, or prevent cancer, inhibit tumors, and ameliorate the adverse effects of radiation and chemotherapy. Plaintiff United States of America Department of Justice (“United States” or the “government”) brought this action against Daniel Chapter One and James Feijo (the “defendants”) under Sections 5(1), 13(b), and 16(a) of the Federal Trade Commission Act, 15 U.S.C. §§ 46(Z), 53(b), and 56(a), alleging that the defendants violated a final cease and desist order of the Federal Trade Commission (“FTC” or the “Com *138 mission”). On September 30, 2011, the United States filed a motion for summary judgment on liability. On September 24, 2012, the Court granted the United States’ motion, concluding that “there is no genuine issue as to any material fact and the United States is entitled to judgment as a matter of law on liability.” See United States v. Daniel Chapter One, 896 F.Supp.2d 1, 17 (D.D.C.2012).

Pending before the Court is the United States’ motion for entry of final judgment. The United States requests that the Court enter a final order that includes injunctive relief, equitable monetary relief in the amount of $1,345,832.43 and a civil penalty award of $3,528,000. Upon consideration of the motion, the response and reply thereto, supplemental briefing by the parties, the applicable law, and the entire record in this case, the Court GRANTS the United States’ motion.

I.Background

Defendant Daniel Chapter One is incorporated under the laws of the State of Washington, with its principal place of business in Portsmouth, Rhode Island. Id. at 2. Defendant James Feijo is the sole member and overseer of Daniel Chapter One. Id. The defendants advertise and sell dietary supplements, including BioS-hark, 7 Herb Formula, GDU, and BioMixx (the “Products”), which they claim can treat, cure, or prevent cancer. Id.

On September 18, 2008, the FTC initiated an administrative proceeding alleging that the defendants’ marketing of the Products constituted deceptive acts and practices in violation of Sections 5(a) and 12 of the Federal Trade Commission Act (the “FTC Act”), 15 U.S.C. §§ 45(a) and 52. Id. at 2-3. Following a trial, an administrative law judge concluded that the defendants had violated the FTC Act by making unsubstantiated claims that the Products prevented, treated, or cured tumors or cancer. Id. Defendants appealed this decision to the Commission, and on December 24, 2009, the Commission upheld the decision and issued a Final Order to cease and desist certain practices. Id.

On January 25, 2010, the FTC issued a Modified Final Order (“FTC Order”). Id. at 3. Part II of the FTC Order prohibits the defendants (referred to in the FTC Order as “Respondents”) from making “any representation, in any manner, expressly or by implication, including through the use of product or program names or endorsements” 1 that any product marketed by the defendants:

[Pjrevents, treats, or cures or assists in the prevention, treatment, or cure of any type of tumor or cancer, including but not limited to representations that:
1. BioShark inhibits tumor growth;
2. BioShark is effective in the treatment of cancer;
3. 7 Herb Formula is effective in the treatment or cure of cancer;
'4. 7 Herb Formula inhibits tumor formation;
5. GDU eliminates tumors;
6. GDU is effective in the treatment of cancer;
7. BioMixx is effective in the treatment of cancer; or
8. BioMixx heals the destructive effects of radiation or chemotherapy; un *139 less the representation is true, non-misleading, and, at the time it is made, Respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation.

Id. 3-4. In addition, Part V.B of the FTC Order requires that:

Within forty-five (45) days after the final and effective date of this order, Respondents shall send by first class mail, postage prepaid, an exact copy of the notice ... to all persons [who purchased the Products between January 1, 2005 and-the date of the obder.]

Id. The notice, which is attached to the FTC Order, informs consumers of the FTC’s conclusion that the defendants’ advertising claims were deceptive because they were not substantiated by competent and reliable scientific evidence. Id.

Defendants filed an appeal with the United States Court of Appeals for the District of Columbia Circuit, contesting the legality and constitutionality of the FTC Order. See Petition for Review, Daniel Chapter One v. FTC, No. 10-1064 (D.C.Cir. Mar. 17, 2010). Defendants also applied to the FTC for a stay of the FTC Order pending the outcome of their appeal, but their request was denied. Daniel Chapter One, 896 F.Supp.2d at 3-4. Defendants then filed with the D.C. Circuit an emergency motion for a stay of the FTC Order. This motion was denied on April 1, 2010. See Per Curiam Order Denying Emergency Motion to Stay Case, Daniel Chapter One, No. 10-1064 (D.C.Cir. Apr. 1, 2010). Because the defendants failed to obtain a stay, the FTC Order became effective on April 2, 2010. See Daniel Chapter One, 896 F.Supp.2d at 3-4; 15 U.S.C. § 45(g)(2).

On August 13, 2010, the United States filed its complaint in this Court seeking civil penalties and other injunctive relief pursuant to Sections 5(1), 13(b), and 16(a) of the FTC Act. Simultaneous therewith, the United States filed a motion for a preliminary injunction seeking an order enjoining the defendants from violating the FTC Order. Daniel Chapter One, 896 F.Supp.2d at 3-4. The Court denied the United States’ motion for a preliminary injunction without prejudice on September 14, 2010, finding that the Court lacked jurisdiction to enforce the FTC Order while defendants’ appeal challenging the legality of the FTC Order was pending before the D.C. Circuit. See Order, Sept. 14, 2010, ECF No. II. 2 The FTC then filed an emergency motion for an order of enforcement

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
89 F. Supp. 3d 132, 2015 U.S. Dist. LEXIS 42751, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-department-of-justice-v-daniel-chapter-one-dcd-2015.